Finanzen von Damora Therapeutics Inc (DMRA)DMRADamora Therapeutics Inc

Evaluating the bottom line, Damora Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -132.85%, provide a clear picture of how effectively DMRA converts its operational activities into shareholder value.

In the context of the broader market, DMRA competes directly with industry leaders such as BCAX and OMER. With a market capitalization of $1.34B, it holds a leading position in the sector. When comparing efficiency, DMRA's gross margin of N/A stands against BCAX's N/A and OMER's 97.20%. Such benchmarking helps identify whether Damora Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has been experiencing significant net losses, with a net income loss of $31.17 million in Q2 2026 and a negative EPS of -0.51. However, it has a strong current ratio of 19.73, indicating good short-term liquidity.